
Changing Physician Workflows Requires More Than Clinical Evidence
Interview with Sonex Health CEO Bob Paulson
About the Guest
Bob Paulson is the President and CEO of Sonex Health, a company pioneering ultrasound-guided procedures to treat carpal tunnel and trigger finger syndromes. Future ultrasound-guided applications will include the treatment of other upper extremity entrapment neuropathies. Bob has led multiple venture-backed medical device companies through commercialization, including NxThera, acquired by Boston Scientific, Restore Medical, acquired by Medtronic, and VentureMed Group. Earlier in his career, Bob held senior leadership roles at Medtronic, Advanced Bionics, and Endocardial Solutions, acquired by St. Jude Medical.
Interview Summary
Founded by two Mayo Clinic physicians, Sonex developed UltraGuideCTR, a minimally invasive device that allows physicians to move carpal tunnel release procedures from the operating room to in-office procedure rooms using real-time ultrasound guidance and local anesthesia, which both expands patient access and reduces the cost of care.
Carpal tunnel syndrome is one of the most common nerve compression disorders, yet more than 80% of patients who need intervention to relieve that compression opt out of a surgical carpal tunnel release procedure because of the recovery times that can be weeks or months before patients can return to normal activities and work. The Sonex Health technology addresses this unmet need by allowing the physician to release the nerve compression with a minimally invasive ultrasound-guided approach using only local anesthesia with a very small (4-6 mm) incision in the wrist that is closed with a Steri-Strip (no sutures required), allowing patients to return to daily activities and work within days. Since the first commercial ultrasound-guided carpal tunnel release procedures in 2018, the company has treated more than 55,000 patients.
Beginning in 2022, Sonex began building a clinical evidence portfolio to support FDA clearance, a new Category I CPT code, and payer coverage, which now includes 21 peer-reviewed publications reporting outcomes data on more than 2,300 patients and 2,800 hands. The published clinical data portfolio includes the largest comparative carpal tunnel release study conducted in the United States, reporting outcomes data on more than 1,400 patients. Sonex has also made significant investments in physician education and training, practice development, and additional clinical studies examining the effect on disparate patient populations and health economics.
Following the January 2026 effective of a new Category I CPT code for ultrasound-guided carpal tunnel release procedures, Sonex expanded its commercial footprint to accelerate the expansion of physician adoption and utilization nationwide.
Top Takeaways
If your technology requires a new reimbursement pathway, FDA clearance is only the first hurdle. Map the evidence needed for FDA, CPT coding, and payer coverage before your first clinical study begins, and design trials that satisfy all three wherever possible. Build a clinical evidence roadmap that answers each stakeholder's questions โ from comparative effectiveness to health economics and appropriate use criteria. That approach influences study design, capital requirements, commercialization timelines, and ultimately how quickly physicians will adopt the therapy.
Therapies that change physician workflow demand a different commercialization strategy. In these cases, clinical evidence alone won't change how physicians practice. Driving adoption becomes an exercise in practice development โ educating physicians and staff, ensuring predictable coverage and payment, supporting providers as they transition to new workflows, and tailoring the commercial approach to match economic incentives.
Build your capital strategy by working backwards from your value inflection points. Understand whether you're building a tuck-in or a fully commercial company, then determine the capital required to reach each value inflection point. Choose investors who can finance that journey by evaluating their fund size, follow-on capacity, and speaking with CEOs they've previously backed. If one investor can't support the path ahead, build the syndicate early.
Sponsors
FastWave Medical: Named MD+DI's Company of the Year, FastWave is one of the hottest medtech startups in the cardiovascular space. See how you can invest here.
Fundraising Cohort: Planning to raise capital for your startup? This live, 4-week workshop, led by Scott Nelson, is designed to help founders and CEOs tell a sharper story, get investor meetings that matter, and close real capital. Join the waitlist here.
Donโt Forget
Interested in advertising with us?
Get in Touch โ
Want to learn from more startup CEOs?
Check Out the Archive โ
Forwarded this email?
Join for Free โ
Who's Scott Nelson again?
See His Bio โ
Transcript
0:00:00 [upbeat music] And so the only way to develop a CPT or a procedure code that will allow doctors to get paid in the office was to go get a new code.
0:00:12 And we, at the time, didn't have the clinical data to meet the requirements either for coding or coverage, right?
0:00:20 That's the thing that you always have to keep in mind is it's one thing to have enough data for either FDA clearance or getting a CPT code, but then you have to have enough data to support coverage.
0:00:31 And so we started this process back in, uh, 2022 of developing the portfolio that would satisfy all three of those.
0:00:42 [upbeat music] Welcome to MedSider, where you can learn from the brightest founders and CEOs in medical devices and health technology.
0:00:51 Join tens of thousands of ambitious doers as we unpack the insights, tactics, and secrets behind the most successful life science startups in the world. Now, here is your host, Scott Nelson. Hey, everyone.
0:01:05 In this episode of MedSider, we sat down with Bob Paulson, president and CEO of Sonex Health.
0:01:09 Sonex's UltraGuide CTR device is a minimally invasive technology that enables ultrasound-guided carpal tunnel release procedures to be performed outside the surgical suite using local anesthesia.
0:01:20 Before joining Sonex, Bob led multiple venture-backed medical device companies through commercialization, including Nex Thera, acquired by Boston Scientific, Restore Medical, acquired by Medtronic, and VentureMed Group.
0:01:31 Earlier in his career, he held senior leadership roles at Medtronic, Advanced Bionics, and Endocardial Solutions, which was acquired by St. Jude Medical. Here are a few topics we explored in this conversation.
0:01:41 First, what it really takes to establish reimbursement for a new medical technology. Second, how to drive adoption when your therapy requires physicians to change how they practice.
0:01:50 Third, evaluating investors beyond the term sheet. And last, how does your most likely exit path shape the company you build from day one?
0:01:58 Before we dive into the full episode, if you're a med tech founder or CEO preparing to raise capital, you should check out the MedSider Fundraising Cohort.
0:02:05 This four-week live workshop combines small group sessions with real-time feedback to help you sharpen your investor story, build a targeted investor pipeline, and run a focused fundraising sprint instead of a never-ending slog.
0:02:17 Over the month, you'll walk away with an investor-ready narrative and deck, outreach scripts that actually get responses, a refreshed LinkedIn profile, a simple content plan that keeps you on investors' radar, and a repeatable system for running your raise.
0:02:29 You can join the wait list at medsider.com/fundraisingcohort. Again, that's medsider.com/fundraisingcohort. All right, let's get to the interview. [upbeat music] All right, Bob, welcome back to MedSider Radio.
0:02:45 Thank you, Scott. Good to be here. I know we were, we were chatting about this before we hit the record button. It's been almost, like, half a decade, right? It's, uh, you know, showing, uh, our age, both of our ages.
0:02:54 [laughs] Exactly. A lot of water under the bridge. No doubt. A lot of lessons learned too. Um, but this time around, we're, we're focusing mostly on, um, Sonex.
0:03:01 You're, the company that you've been focused on for, for several years now.
0:03:04 And so, uh, before we get there, though, for those that didn't listen to our previous interview and are maybe loosely familiar with your name but don't know a lot about your background, let's start there.
0:03:12 Give us, like, the one- to two-minute kind of elevator style, you know, bio on, on your, your experience in the device space over the past, uh, couple decades. Good.
0:03:20 Well, so I started my career actually, uh, at General Mills doing consumer packaged goods stuff. Then, uh, had to scratch the itch to go to law school.
0:03:28 Went back to law school, practiced corporate law for several years, went back to General Mills and then in the, uh, early '90s, got the opportunity to go over to Medtronic just after Bill George became CEO.
0:03:39 So I spent about seven years at Medtronic doing corporate development, corporate strategy. We did, Medtronic did a bunch of acquisitions back in the late '90s.
0:03:48 One of them was Softorganic, spine company, and I had the chance to do that deal, lead the integration, and then go out and run the surgical navigation business out in Boulder.
0:03:57 And did that for two or three years and, uh, just never lost the urge to step over to the other side and do the work for a venture-backed startup.
0:04:06 So first went to Advanced Bionics in Valencia, and then from there to Endocardial Solutions here in the Twin Cities, and then did a company called Restore Medical, which was in the ENT space.
0:04:19 Uh, and after we sold that to Medtronic, w- that was followed by Nex Thera, which was at a, a vapor ablation technology to treat prostate conditions, beginning with BPH. Uh, we sold that to Boston Scientific in 2018.
0:04:33 I helped a friend with a vascular company for a couple years and then joined Sonex Health back in late 2021.
0:04:40 I'd-- one of the founders for quite a while, and it was, uh, the investor who had come in, was looking for an experienced, somebody who'd been there, done it a few times, to come in and help grow the company.
0:04:52 And we actually, uh, had already, Daryl had already hired our commercial team leadership from Nex Thera to come over here to Sonex because it was another office-based disruptive technology, taking a procedure out of a, out of an OR suite and moving into the office.
0:05:07 So kind of put the band back together here at Sonex and, and, uh, we've been, uh, making great progress here over the last four and a half years. Yeah.
0:05:14 And, uh, we're recording this in, uh, call it mid, let's call it mid 2026. You've been at it for almost, almost five years now. Looks like it, yeah.
0:05:21 It looks like based on, got your LinkedIn profile, uh, in front of me here, and, um, we'll definitely link to that in the full write-up on MedSider.
0:05:27 But for those that aren't familiar with Sonex, you know, we're at July 4th get-together, and I- Yeah... I know very little about this company. Like, what is it? What, what's the technology?
0:05:35 Like, if I'm a patient, how do I get access to it? Like, tell me more about it.
0:05:38 So Sonex Health was founded by two, uh, male physicians, uh, both of whom were sports med docs, uh, PM&R, who had a lot of expertise in ultrasound, and they were seeing a lot of patients in their clinic post carpal tunnel procedures.
0:05:52 So upper extremity, extremity neuropathies and entrapments, where the traditional approach to relieve the impingement is to, uh, make a surgical incision, do a cut down to wherever the impingement's occurring, cut the impingement, and then stitch the patients back up.
0:06:07 And the biggest challenge with- All these procedures is the wound healing and the, the difficulty patients experience. And because of where the location is, it impedes your ability to return activities and work.
0:06:19 So of all of those various impingements that are out there, carpal tunnel syndrome is the largest of those markets.
0:06:26 And the, the focus of the company was to develop a device that could be utilized in conjunction with ultrasound to take procedures out of the OR, move it into a, a procedure room, whether that's an office, an ASC, or a hospital procedure room.
0:06:41 But doing it in an, a percutaneous or minimally invasive approach that allows the patients to return to activities in, in days versus weeks or months.
0:06:49 And so we're now at the first commercial procedures with our device was done 2018, and we now have treated over 55,000 patients. So- Wow...
0:06:59 in, in summary, the, the opportunity is that 80% of the patients diagnosed with carpal tunnel have been told it's severe enough, you need a procedure, you need surgery, are choosing to avoid surgery because they can't afford to be out of work for weeks or months while they recover.
0:07:15 And so the opportunity here is in performing this minimally invasive approach that's used as only local anesthesia. We close it with a, a pressure bandage or a, a Steri-Strip.
0:07:26 Uh, no need for sutures, and a very small four to six millimeter incision in the wrist, and patients are back to activities in two to three days, uh, back to work in three to five days as opposed to several weeks or months that's common following a surgical carpal tunnel procedure.
0:07:42 Never ceases to amaze me, like, some of these, like, massive problems, right?
0:07:45 Carpal tunnel, I think almost everyone that's listening to this has n- either maybe has experienced a mild form of it or some sort of, like, something adjacent to it. Yeah.
0:07:52 The, the CEO has had the, a simultaneous- Oh, there you-... bilateral procedure. It was something, yeah... there you go. Yeah. It's so... It's terrible. I mean, right? Like, I don't- Horrible.
0:07:59 Yeah, it's, it's horrible, and everyone, I think, is probably nodding their head like, "This is awful." But yet, not a lot of great solutions until something like Sonex come, comes along.
0:08:08 In terms of the technology itself, like, what, what's actually happening? Like, uh, so it's obviously incredibly minimally invasive.
0:08:13 Sounds like the, the recovery is pretty quick, but, like, what's, what's the physician actually doing? But tell me more a little bit about the, the science.
0:08:19 So the device that, that we developed is a device that's optimized for ultrasound and for the anatomy, for ultrasound, for a local, a procedure that can be done with local anesthesia.
0:08:31 Uh, so the device is actually, it's a very... Like most, it's complex, but yet it's very simple, right? So it's got... So four to six millimeter incision in the wrist.
0:08:40 The doctor's holding an ultrasound transducer in one hand so they can visualize the entirety of the anatomy, and then the device is inserted through that four to six millimeter incision in the wrist.
0:08:51 So you're staying away from the palm of the hand, which is where a lot of the difficulty comes if you do a surgical approach.
0:08:58 And navigating under real-time visualization the device through the carpal tunnel, and under ultrasound you can see all the anatomy. You can see bones, you see ligaments, tissues, nerve.
0:09:09 Most importantly, you see the nerves, right? And that's the biggest, uh, thing you need to avoid.
0:09:13 The critical anatomy in the carpal tunnel is the median nerve on one hand, uh, or one part of the hand, and the ulnar artery that's coming down from, from the upper arm and the other part, and both of those converge in the carpal tunnel.
0:09:27 And so the device has integrated into the shaft of the device are two balloons that are inflated with saline.
0:09:34 You can visualize that under ultrasound, as well as the fact that as those balloons are inflated, it creates additional safe space in the, in the carpal tunnel.
0:09:44 There is a recessed blade in the tip of the device that within the safety mechanisms of the design cannot be deployed until the balloons are inflated. So that way you know you've got a safe.
0:09:55 The doctor can both visualize the placement of the shaft. They can see the balloons. They're echogenic. And then the blade's deployed, and you're distal to where the transverse carpal ligament...
0:10:06 The issue is the transverse carpal ligament's rubbing on the median nerve and then trapping it, and that's what's causing the pain.
0:10:12 And so once you're underneath the TCL, you can visualize that on ul- ultrasound and the blade's deployed.
0:10:19 And then with an actuator, a thumb actuator on the device, the blade is pulled back along a track in the device and cuts the TCL.
0:10:27 The doctor can then both visually and tactically confirm that they have a complete release. Device is removed, uh, Steri-Strips applied, pressure bandage, and patient walks out and drives themself home if they want to.
0:10:41 Okay. [laughs] That, that's super. And now I'm on the website now, and there's, there's, like, a really...
0:10:44 There's some really helpful videos if you're, uh, listening to this and curious to learn a little bit more about kind of what's actually happening during the, during the procedure.
0:10:50 But like you mentioned earlier, it's like, it's simple to the patient but pretty complex in terms of, like, how you've engineered the device, it sounds like. Yep. Yeah.
0:10:58 You mentioned, uh, over 50,000 procedures now performed. Kinda give us a, a high level overview of kind of where the company's at. I mean, is it full on, like, global commercialization?
0:11:07 Are there geographies that you've prioritized? Like, where, where's the company at as of mid, mid 2026? So we're, we're US only by design, so we're commercial.
0:11:15 As I said, we've done 55,000 procedures to date, and that's been accelerating over the past several years.
0:11:20 The biggest challenge the company faced when I joined the company was that physicians were billing the procedure using an existing carpal tunnel release code, which the descriptor actually fits, but it doesn't...
0:11:35 It's a surgical approach, and it doesn't pay- Mm-hmm... in an office setting. And these are both the endoscopic and the open codes have been around for 30 years.
0:11:45 And so there was, uh, little interest on the part of the society in modifying the existing code.
0:11:52 And so the only way to develop a, a CPT or a procedure code that will allow doctors to get paid in the office was to go get a new code. Mm-hmm.
0:12:02 And we at the time didn't have the clinical data to meet the requirements either for coding- Or coverage, right?
0:12:10 That's the thing that you always have to keep in mind, is it's one thing to have enough data for either FDA clearance or getting a CPT code, but then you have to have th- enough data to support coverage. Mm-hmm.
0:12:21 And so we started this process back in, uh, 2022 of developing the portfolio that would satisfy all three of those in the course of the last couple years.
0:12:31 I guess it was last year we actually introduced a second generation device where we made some significant improvements both in terms of, of taking or making the device even more user-friendly.
0:12:43 And so form factor, things that you'd learn over, we've learned over the first 45,000 procedures.
0:12:47 The device worked exceptionally well, but as always, it's a, was a first generation device and there's opportunities to improve. And then we also took, um, a significant...
0:12:57 By being able to be much more specific, we took significant cost out of the device.
0:13:00 So cut, cut about 40% of the cost of goods, uh, reduced cost goods by about 40%, which gave us now a very nice, attractive gross margin for the product.
0:13:12 So the last four years has been, uh, and again, one of the requirements, as you know, Scott, for a new CPT code is widespread adoption, so you have to be commercializing in order to hit that, um, somewhat arbitrary threshold that's decided on a case by case basis.
0:13:28 And so we kept the commercial organization flat through, through, over the three years. So '23, '24, '25, kept the organization flat at about, uh, between 8 and 10 territories.
0:13:41 And as the new code was approved in the fall of '24, it went through the rec process in '25, and it went into effect in January '26.
0:13:50 So concurrent with that, we've now had the first expansion of the sales force with the new code and are going through the process of, of ensuring that the coverage is kinda consistent across the country and, and beginning to ramp, ramp adoption utilization.
0:14:06 You certainly climb the reimbursement mountain, [laughs] the coverage and reimbursement mountain. [laughs] We've climbed and now we have to make sure that we can stay on top of it, right? Yeah.
0:14:14 It's, it's a, it's a process that is, that is, uh, opaque through everything.
0:14:20 I mean, it's, it's opaque going through the CPT process and, and the rec process, and it's opaque from a payer standpoint as you have to be able to track claims or claims being paid.
0:14:31 You know, a lot of doctors with a new code, their inclination based on experience is to treat a few patients and see if they get paid, but that's a three to four-month process typically between the time you do a procedure, claims submitted, and the payment comes in the door.
0:14:47 We needed to, um, accelerate that. We're very confident Medicare patients would get paid, but Medicare is probably, depending on the state, 30 to 40% of patients. Mm-hmm.
0:14:58 This is a condition that affects a lot of working age people, so we needed to make sure that the, uh, docs would continue to treat patients commercially and submit claims because that's the only way you know if the payers are paying.
0:15:12 Mm-hmm.
0:15:12 And so we put together some, some creative risk sharing programs to incentivize docs to file claims through a third party reimbursement group that we're working with who can, who can submit the claims and then appeal the claims if there's any denials.
0:15:27 And, you know, knock on wood so far, if the industry average is 25 to 30% approvals in the first year of a new category one code, we're running, we're running the high 80s, um, six months in.
0:15:40 But knock on wood, I mean, there's no guarantees obviously- Mm-hmm. Yeah... but way better than the other end of the scale. Right. So we're, we're cautiously optimistic.
0:15:48 And, and again, uh, in large part because, you know, the reason payers deny claims typically is either it's patient selection, right?
0:15:57 It only, it works for certain patients and not others, and that selection criteria is not clear. It's because you don't have enough clinical data to support the, the new procedure and/or it's more expensive, right?
0:16:11 Those are the three primary reasons why new procedures, new codes don't get paid. And for us, this is carpal tunnel. It's the exact sa- all three, both surgical approaches and our approach are all doing the same thing.
0:16:24 You're transecting the transverse carpal ligament to relieve the, the impingement, and there's no patient selection criteria involved. If you've got carpal tunnel, you got carpal tunnel. You have to have the TCO cut.
0:16:35 Secondly, in terms of clinical data, we're now sitting at 21 peer reviewed publications on- Wow... 2,300 patients and 2,800 hands.
0:16:46 And why that's important is that because of this approach that's so minimally invasive, it can be done with local anesthesia, it enables bilateral, simultaneous bilateral procedures.
0:16:58 And bilateral carpal tunnel is, is highly prevalent. Over 50% of patients suffer in both wrists, the condition. So that's great on the patient selection, uh, the da- the data to support the patients.
0:17:11 And then lastly, because this is, this can be done as an office procedure, it's done in the lowest cost site of care, so it's, the health economics are, are positive compared- Mm-hmm... to surgical procedure.
0:17:23 You're not using an OR suite, you're not using anesthesia, you're not using a PACU post-procedure, and you're not using rehab services post-procedure for rehabilitating a deep incision.
0:17:34 So we're on the right side of the clinical e- equation. We're on the right side of the cost equation.
0:17:39 And, you know, that was the intention back four years ago to get there, but it's a long, it's a big investment, uh, to do all those studies.
0:17:48 Uh, we just completed enrollment of the largest carpal tunnel st- comparative carpal tunnel study ever done in the United States. It was over 1,400 patients. There were three arms.
0:17:59 One was a ultrasound guided arm, and then there were two comparator arms, one open, uh, surgical procedure, one endoscopic. And we'll end up with probably six or seven publications out of that.
0:18:10 Um, but the first, the first bolus of data to compare to our arm studies and then the ultrasound guided arm is, is out. The, the, uh, Medicare H patients is coming.
0:18:21 The sight of service paper's coming, and then we've got a health economics paper that's, uh, will be coming. All four of those will be coming in the back half of the year. Yeah.
0:18:28 See a, a lot of that, lot of that work over the past [laughs] call it handful of years really, you know, kinda- Yeah... now servicing, uh, coming to fruition. That's such a, a, I mean, huge congrats to your team.
0:18:37 I mean, it's such a huge lift, you know, not, not- Huge, huge lift. It was, yeah... not just in terms of capital, but just the sheer amount of work that goes into establishing a new CPT code.
0:18:45 When you think about that, um, and maybe we'll get into this in a little bit more detail, but if I'm new to this world, right?
0:18:50 Like say, for example, I've worked in, in, with technologies that mostly utilize an existing code.
0:18:56 General framework for other founder CEOs that are maybe, maybe facing the same, the same thing that you did when you first came into, um, uh, Sonex. Is it five years? Is that kind of a rough, a rough number?
0:19:05 Is it f- three to five years, something like that? You know, it used to be you'd get a 510[k] through commercialized and get to 35 or 40 million in revenue on 40 to 50 million of invested capital- Mm-hmm...
0:19:18 in three to five years. And it's just really hard to do that now because if you think about the process of getting...
0:19:24 If you have to get a new CPT code, so obviously, I mean, you start at the beginning and one of your first questions has to be, you know, y- you size the market, right? Mm-hmm.
0:19:33 What's the MNK, what's the accessible market, blah, blah, blah. But then the next question needs to be, okay, does this fit within an existing code?
0:19:41 And if so, that's one criteria, but if it doesn't and you're gonna need a new code, then you really need to flesh out, you know, what's required to get FDA clearance, how much of that is leverageable and/or what's gonna be required to get a new Cat one code.
0:19:59 Mm-hmm. And then once that code is issued, what data's gonna require for payers to pay. So it's really a three-leg process. You need to design,
0:20:11 to the extent that you can, those early studies where the data not only meets the FDA requirements, but it meets what's gonna be required for CPT and what's gonna be required for payers. Mm-hmm.
0:20:22 And that, that adds complexity to the study, right? Because a lot of things that...
0:20:26 And understand if there's gonna be comparative data, does that mean it's, if you don't have to do an RCT for a randomized controlled trial for the, for FDA, are you gonna have to do one, are you gonna have to do some other kinda comparative study to get the Cat one code, which has a requirement for a level one or a level two A study.
0:20:45 So- Mm-hmm... and that's gonna go to how much capital you're gonna need, how much time it's gonna take, what kind of follow-up.
0:20:51 You know, if you're, if you're in a situation where FDA is gonna require one-year follow-up, then, you know, presumably whatever development time it takes you to start that study, that's typically a minimum of 18 to 24 months- Mm-hmm...
0:21:06 from the time you start the study to when you get one-year data published.
0:21:10 And then assuming you can develop an argument that meets widespread use without commercializing first, then the process of getting a CPT code in the year that it, the code is approved, the following year is the ruck process, and it doesn't go into effect until January of the year after.
0:21:29 So- Mm-hmm... if you have to get a new code, it's gonna be probably five to seven years. Yeah. Okay. Yeah. This is a good framework for those that are kinda staring down maybe something similar.
0:21:38 So I wanna use the next half hour to kinda get into some functional topics and really kinda try to glean some, some key lessons learned that you've picked up on, you know, over the past couple decades running a fair number of startups.
0:21:48 Um, but again, for everyone listening, we'll link to it in the full writeup on, on MedSider, but it's Sonex Health is the website, S-O-N-E-X Health, um, just as it kinda sounds, sonexhealth.com.
0:21:58 Highly encourage everyone to kinda check out the technology if you're certainly a provider, but also if you're a patient or h- know someone that's suffering from carpal tunnel, like this is, uh, definitely something that you shou- you should consider.
0:22:07 So Bob, first question I have for you is, is kinda, kinda zooming out and thinking about all of the startups that you've been involved with, right? For, for quite some time now.
0:22:15 Uh, multiple kinda exits under your belt as well. Are there like a couple key things that you've, you know, you've really focused on integrating into, into Sonex over the past handful of years?
0:22:24 You know, whether it, that's, you know, previous mistakes or things that you, you know, you, you did right over the last years that you really kind of really try to instill and, and integrate into, into Sonex.
0:22:33 You know, I think y- y- you always start with making sure you understand what your investors' expectations are, what their time horizons are gonna be, right? So where they are in their, in their fund life.
0:22:47 So you, you have a business plan and you lay that out, and it's gonna take X number of years. If it's a 10-year fund life, where are they in their fund life? You've laid out your capital requirements.
0:22:58 Do you start with one investor? Do you need to put a syndicate together in the beginning that can take you all the way through the process?
0:23:05 And then in parallel with that, understand, you know, what the market requirements are in terms of how strategic you're looking at this market. If you have a... What's a good example the past few years, right?
0:23:17 If you had another TAVR design, then you knew it was a, it was an arms race on IP, and so therefore, if you could prove that it worked, let me think about six that Medtronic acquired.
0:23:32 They acquired it on, you know, patient data of less than 10 patients, right? So they just had to prove that it worked, and because of, of where the IP was, uh, that was enough to get a strategic to move.
0:23:42 That's the exception. You know, normally, you know, there are, there are only a handful of companies that will acquire early stage- Mm-hmm... tuck in.
0:23:51 So if you have a product that, that will fit in somebody else's bag, then through discussions, whether it's with bankers or folks at the companies that are interested in the market opportunity, what do they need to see to be able to, to tuck that in?
0:24:06 And how does that fit with your investors' interest?
0:24:09 Or if their expectations are a higher return, then you probably have to go through commercial expansion, and then it's typically You know, it needs to be non-dilutive inside of a strategic within a year- Mm-hmm...
0:24:24 maybe two years, depending on the market opportunity.
0:24:26 And then you have to go put it in reverse and figure out what's it gonna take to get there to achieve those value inflection points that will either bring in additional capital. You can't count on an acquisition.
0:24:38 Companies get bought- Yeah... they don't get sold. Mm-hmm.
0:24:40 So you've, you've gotta be able to say, here's a value inflection point, and we'll be able to do a market check here, and if not, then we need to bring in additional capital that's gonna take us through the next stage and the next value inflection to get to the next value inflection point.
0:24:55 Mm-hmm. So that's probably the biggest lesson. And, you know, we had that long reimbursement discussion, that's part of it- Mm-hmm... because bigger companies tend not to be...
0:25:03 they tend to be good at helping facilitate codes, but if they have to start from scratch, that's oftentimes that's an overwhelming...
0:25:12 That means they're not gonna be able to generate the revenue internally until that predictable payment is there, or at least the light at the end of the tunnel is there. And so that's just gonna be a factor. Yeah. Yeah.
0:25:26 I'm not sure if you know Dan Rose. Yeah. He's the CEO of Limflow and E2 now, running E2 now. We were chatting about this the other day.
0:25:31 Uh, like, it sounds cliche, but like thinking about all the, all the things that need to come together for a successful liquidity event, whether that's a, in most cases, an exit in our, in our space to a strategic, in some cases maybe it's an IPO.
0:25:43 There's like so many things [laughs] that have to, have to go right.
0:25:46 And in your case, you know, you're, you're, uh, I think you're building even, even in a more challenging environment 'cause you've gotta have, you know, you've had to do all the, all the work that, you know, leads up to a, a, a CPT, uh, a cat one CPT code.
0:25:56 And so the comment that you made earlier, like, I guess out of the gate, was just alignment early on, right? Thinking through like, is this a, is this a tuck-in play, right?
0:26:04 Is this a, is this a play where I need to go generate a CPT code, right? To, and, and commercialize this fairly extensively.
0:26:10 I mean, just having, like, being able to kind of see five to 10 years down the road, so, so crucial even in those early, even in those early years.
0:26:17 [upbeat music] Hey everyone, let's take a quick break to catch you up on MedSider Courses. These eight-week courses are designed to help you learn winning formulas from world-class CEOs.
0:26:25 MedSider Courses cover topics like fundraising, device design and development, clinical and regulatory strategy, commercialization, and M&A.
0:26:32 Each course covers the hard-earned lessons shared by the med tech founders and CEOs who join our program.
0:26:38 MedSider Courses can be purchased individually, or they're included at no additional cost with the MedSider All-Access Pass. You can explore MedSider Courses at medsider.com/courses. Again, that's medsider.com/courses.
0:26:51 Okay, let's get back to the conversation. 100%, because, I mean, look at the, the public equity markets haven't been available for early-stage med tech for years. It used to be a very, a very viable option.
0:27:09 That hasn't been the case for, I can't remember since how long, since early-stage companies.
0:27:13 There were a couple of windows, but, and now we're in a situation where, you know, you've got companies with 100, $200 million in revenue are, are stacked up waiting for the markets to open. Mm-hmm.
0:27:24 So you have to assume that's not gonna be a viable exit strategy in the next two to three years at least, right?
0:27:32 And then the other challenge has been, if you go back to, to 2008, when the markets crashed in 2008, one of the challenges, so the IPO markets dried up obviously, and the large med tech, large caps, uh, to grow, they had to do so by acquisition, right?
0:27:49 And so you had, uh, first the, you know, the big guys pretty much acquired all of the, the mid caps- Mm-hmm... the $2 to $500 million companies.
0:27:59 And then you started to see the merger between the large caps, and there now there's just a handful of large cap companies that- Mm-hmm...
0:28:07 that are still in the M&A, and there's only a couple, Stryker and, and Boston, that have kind of systematically grown by acquisition over the last few years. And, and they, they do, do, uh, tuck-in deals, right? Mm-hmm.
0:28:21 Not to say it doesn't happen elsewhere, but it's, it's kind of a onesie, twosie market specific kind of thing. So depending on the market that you're in and recognizing that,
0:28:31 you know, to get inside of a large company now and un- and get them to be a logical acquirer means you have to be on the strat plan.
0:28:40 If you think about an annual strat planning process that concludes inside of a company in August, it rolls up to the boards in September and October, operating plans are finalized for the next year.
0:28:51 If you're not on the strat plan, if your technology or your market is not on the strat plan and you're not there as a, as a company, it's gonna be another year typically before, you know, it's gonna be considered.
0:29:03 So again, those are just considerations. So you need to be, use your contacts inside of the individual business units within big companies and look at, they're, they're all fighting for capital too, right?
0:29:14 I mean, it's a capital allocation game inside of every large med tech company. And so there are just lots of factors that need to be considered- Mm-hmm... as you, as you map out your, your path.
0:29:24 Lots of things that seem like...
0:29:26 I'm, I'm nodding my head as I, as I hear you kind of explaining a lot of this stuff, but it's like it, until you've kind of been through the mix, uh, it's, it's hard to really kind of truly understand, um, you know, some of these topics.
0:29:35 But on that note, I want, I wanna do, I wanna circle back around to something you mentioned earlier, talking about, about reimbursement and the, and the, and the sheer amounts of data that you, you've collected for, for Sonax over the past handful of years.
0:29:46 When you think about balancing the data that's, that's needed to generate or to convince a physician, right? To begin to accept- Yep...
0:29:51 to adopt this technology, use it on their patients, versus something that a payer is gonna get behind, right?
0:29:56 And, and you're even, you've been able to, to kind of get over even a higher hurdle because your mix of patients is, is largely private payers, right?
0:30:03 It's not necessarily CMS, and so there's, you know, you gotta go out and convince all of these, all of these payers to like, cover the technology too.
0:30:09 So when you think about that balance, right, what's needed for physicians versus what's needed for, for patients, how are you kind of thinking about that as it, as it pertains to kind of designing some of this, some of this clinical work?
0:30:17 So you go back to the, the condition, right? So this isn't- What's a good example? It's not like I've got the next pain stimulation technology for the spine, right? Mm-hmm.
0:30:27 And so to be able to differentiate, so I'm stimulating this nerve versus that nerve, and here's the data to demonstrate that the efficacy is equal to, better than, safer, more effective, whatever.
0:30:39 In this case, in our case, it's fortunately more simple. Everybody does the same thing. They cut the, uh... they, or they transect the transverse carpal ligament.
0:30:49 So the clinical data required for clinical adoption was, and is, less of an issue than moving surgeons who...
0:31:03 So our, our biggest challenge has been hand surgeons are not trained in ultrasound, right? Mm. They're... They, they cut. They open up. They look. They visualize. They do whatever they're gonna do, right?
0:31:14 So whether it's nerve procedures or repairing broken bones, you do it through an incision. You visualize. They all know the anatomy, but we have to teach, we have to teach them ultrasound.
0:31:23 How do you recognize the anatomy you already know in 2D black and white? Now you get 3D by doing the short view and long view with a transducer, but now you're interpolating that in your head. Mm-hmm.
0:31:36 And what's been fascinating is you see the older, more experienced surgeons struggle with that, whereas the young surgeons who grew up on video games- [laughs]... and gaming, um, and using two hands to...
0:31:50 It's, they pick it, I mean, right there. They're... You, you show a resident this and go, "Oh, okay. Boom, boom, boom." [laughs] That's easy, right?
0:31:56 They're not gonna do a procedure for two or three years because they're in residency, but there's a learning curve. So education and training has been a key part of- Mm... what we have to do.
0:32:06 And then back to reimbursement. Funny thing, if docs don't get paid, they don't wanna do the procedure, right? Mm-hmm.
0:32:11 So to be able to convince them to put the time in to train on ultrasound and do this procedure, they have to know they're gonna get paid.
0:32:21 Because the first part of our company, the majority, over 70% of procedures were done in hospital procedure room settings. That means you had to go through VAC committees, right? Mm-hmm. And so that adds time to the...
0:32:35 So no surgeon's gonna say, "Okay, yeah, I wanna spend the t- I'll invest the time to learn ultrasound until I know that the VAC is- Mm... gonna approve this as a, as a new product or procedure."
0:32:49 And so it's, it's more than just a little bit of chicken and the egg because how hard are they gonna advocate if they haven't really done the procedure yet, right? Mm-hmm. To say this is better for the patient.
0:32:59 They get it, and it happens, but it made the timeline between I'm interested and I'm doing commercial procedures much longer than is viable long-term, right? Mm-hmm.
0:33:11 So now that there's predictable payment, the biggest time challenge has been now convincing surgeons who have done almost all their procedures in hospital or ASC settings, surgical suites, now getting comfortable doing it in the office.
0:33:26 Mm. Now, a lot of other specialties have done this and, and our team has done it in ENT. We did it in urology.
0:33:34 So it's not cut and paste, but it's you, you know what needs to be done, but then it's getting first the physician comfortable and then getting their staff comfortable that they can do these procedures in a office procedure room.
0:33:49 And it, it means they have to change their normal flow. It means they have to change how they schedule. And so this is really practice development. It's not just a matter of, "Hey, do this in the office."
0:34:00 They don't know how to do it. They don't know how to, you know, set up the- Mm-hmm... even though the, the supplies required for this are minimal, you still have to package it. You have no OR suite.
0:34:11 I mean, if you're in the OR- Mm... somebody takes care of all that, right? Yeah. By doing it this way, we're taking over 80% of the waste in terms of sterile sheets and- Mm-hmm...
0:34:21 sterile drapes and this and that and the other thing. We're taking all that out of the equation, and it works really, really well, but you have to teach them. Yeah.
0:34:28 And it just takes time, so that means your field organization has to be able to be there to support and get the staff comfortable in using ultrasound.
0:34:38 And if you, if you're in an office that we're in a practice where there's staff turnover or there's not staff dedicated to a physician, then that's something else that they have to do is...
0:34:48 Because now you're teaching a PA or a mid-level how to run the dials on an ultrasound machine. Mm-hmm. The doc has a device in one hand, a transducer in the other.
0:34:56 Someone still has to, you know, take the picture for the, for the patient record on the file and it's just... So it's just training. It's not, again, it's not rocket science, but it's, it's a consideration. Yeah.
0:35:07 Just hearing you kind of ri- riff on this topic, the technology has to be compelling enough, right?
0:35:11 It has to be super compelling enough to convince all of these kind of downstream things to put all of these downstream kind of things to- together, right?
0:35:18 And so, you know, hearing you explain the technology at the outset of this episode, it's like it seems like a no-brainer, right?
0:35:24 It's like kind of same, same underlying thing that you're, it, uh, you're trying to do as a, as a physician, but, like, way more minimally invasive, way faster, with pretty easy recovery.
0:35:34 Now they get paid to do it, et cetera. Should be no-brainer, right?
0:35:37 But then thinking through, like, all of these workflow related, um, you know, challenges too, it's like you've really got to have a compelling technology that gets people to lean in, to willing, willing to kind of change a lot of things, a lot of things, yeah.
0:35:47 You, you really need, you really need... I mean, you hit on a really key topic- Mm... Scott, because you need motivated physicians, right? Yeah.
0:35:54 So part of what we, our, our team has to do is we can't afford tire kickers. I mean- Mm...
0:36:00 the time it takes to get through training, the amount of time that we have to invest in terms of multiple visits to a site to help the doc get up to speed, make sure they're there, we can't do it.
0:36:11 Doc say, "Well, let me treat three to five patients and see how they do." Mm-hmm. No. I mean, that's not, that's gonna be someone say, "Thank you. I'm glad you're interested. We'll come back when you're more interested."
0:36:21 Mm-hmm.
0:36:21 Because we have to be willing to- Invest in the process to be able to do it, and 100% of the time, if you go to a high-volume surgical carpal tunnel release surgeon and say, "You know, here's this minimally invasive approach, and all my patients all do just fine."
0:36:38 Okay? Yeah. And they say that because they never see the patients back, right? Mm-hmm.
0:36:42 They do the surgery on the patient, and when the patient has to come back a week, 10 days later to have their sutures removed, doc doesn't see them usually. Mm-hmm. The mid-level or the PA sees them, right?
0:36:52 Takes the sutures out, and then the patient's, "Oh, I'm having all this pain." And, "Okay, well here's the, here's a physical therapy appointment."
0:36:59 So then you go to weeks of physical therapy, and you're only gonna see a doc again if there really is an issue, and the complication rate is not that high with the surgical procedures.
0:37:10 So it's really, it's a patient-driven- Hmm... it's a patient-driven matter, and payers don't care, right?
0:37:17 The fact that the patients are back to activities in, in three to five days, back to working activities in three to five days, they don't care about that. Mm-hmm. All they care about is the cost.
0:37:25 So you have to appeal, the you appeal to the doctor is, first of all, that your patients are gonna do a lot better, and they're gonna be a lot happier.
0:37:35 So when they have to come back and have an elbow, a shoulder, or if you're an integrated practice, a hip and knee done- Mm... "My God, I got back to my activities in two to three days. This is the practice to go to."
0:37:45 And then they have to be able to wrap their heads around the economics of they can in fact generate more net revenue by doing this in the office than going over to an ASC or a, a hospital outpatient where they're just being paid on their work RVUs.
0:38:03 Mm-hmm. And so that's the third leg of complexity for our sales team is you've got to understand how that doc's complicated. Mm-hmm.
0:38:12 And as more and more practices are being acquired by PE firms and hospital systems, now you have a hos- sys- hospital system-based employee. You need to figure out, are they do- are they flat salary? Hmm. So Kaiser.
0:38:25 Yeah. Kaiser as an example, they're paid a flat salary. They have no incentive to do more or less. Hmm. All they're incentivized to do is do what's in the best interest of the patients. Yeah.
0:38:33 And so the fact that they can make more money doing the office, they don't care. Yeah. It's not, not part of it, right?
0:38:39 Now, if you're a hospital-based employee and you get paid based on work RVUs, then you're gonna be adding up, now is that your base, or is that just your incentive, or is that for next year? Mm-hmm.
0:38:49 And so you've got to kinda craft the story. You need to understand the economics of the doc and the practice- Mm-hmm...
0:38:56 and then shape your rationale or your, your advocacy about why they should invest the time to do this and how it's gonna impact their compensation.
0:39:06 Is there, like, a direct-to-patient kind of aspect of this, or are you primarily relying on these high-volume clinics in a local geography to kind of do a lot of that, kind of take the baton and, and- Yeah...
0:39:16 become bec- you know, they, they want to already be known for, like, the, the, the most patient-friendly practice? It always starts with... What's a good ex- Think about Inspire.
0:39:25 It always starts first with the docs, right? And until you... It's a pitcher-catcher situation. Until you've got the catcher set up in a market- Hmm...
0:39:34 so that if you go direct to patient on a broad basis, you advertise that if a patient walks into the office, they're going to get an ultrasound-guided procedure, right?
0:39:44 The last thing you wanna do is pay money to draw patients or to drive patients. And it's like any kind of advertising.
0:39:51 If you advertise Cheerios, and you go to the grocery store and the Cheerios aren't on the shelf, you're gonna buy something else, right? Yeah.
0:39:57 You go into a practice that maybe one doc's doing the procedure, but the other three hand surgeons are not. Patient comes in, gets assigned to whichever doc has an opening, and they don't offer it.
0:40:08 So it's a timing issue.
0:40:10 That said, where we do have practices that are set up, if the market opportunity is the fact that 80% of patients who need a surgical carpal tunnel release procedure are sitting on the sidelines, doc, that means 80% of your patients that you could do this on are s- And they always say, "Oh, no, no, that's not.
0:40:26 My patients all- Yeah... are, do fine." Mm-hmm. And then you show them the data.
0:40:31 Um, you show them AcuityMD data that shows that they had, here are all the referrals that came into them from carpal tunnel, and here's the number of procedures they did.
0:40:40 And so where did all those other patients go, Doc? And so the answer is they're waiting for a procedure, so y- they're not willing to do a surgical procedure. Hmm.
0:40:48 So then we can help them with, we have a number of programs where we'll do direct to patient within their practice, and the response rates of these things have been absolutely amazing. Hmm. We'll have...
0:41:00 It is not at all unusual to have 50 to 75 patients show up for- Wow... a physician education seminar, right? Why? 'Cause they're already diagnosed. They already know they have carpal tunnel, right? Yeah.
0:41:12 And of those patients that show up, it's very common to see 50 to 75% sign up for a procedure that night. Wow. So they'll commit.
0:41:21 They'll go on a schedule, and the doc then is just set up, depending on how many days a week they're doing this, they've just, you know, filled their, their pipeline for the next two, three, four weeks. Yeah.
0:41:31 It's one of the, one of the nice things, I guess, about, about solving such a, a glaring need, right, in carpal tunnel [laughs].
0:41:36 It's like if you have it, it's so terrible and it's so painful, it's like, uh, pretty much do anything that's, uh, uh, to, to solve for that, right?
0:41:43 Especially, especially if it's, like, you know, something pretty novel and way, you know, re- requires way less recovery time, et cetera. So yeah, that's, that's a good explanation.
0:41:52 I like the pitcher-catcher analogy that you used, too, 'cause that's so, so crucial if you've got, if you're working on a technology that does have this kind of direct-to-patient element.
0:41:59 I, I know we don't have a ton of time left, but I wanna get your take on, on capital strategy, right? Yep. 'Cause you've raised a lot of capital over your, over your career. Seen a lot of the, the ebb and flow, right?
0:42:08 And you touched on some- Yeah... of this earlier from, like, the, the cha- you know, how, how the market has changed kinda post, post kinda 2008 timeframe, et cetera.
0:42:14 So if you're trying to coach up a newer CEO on how to, how to go from kinda maybe some pre-seed money to now raising from institutional investors in their series A or series B and beyond, are there a few things that you typically kind of, uh, advise other, other newer, younger CEOs?
0:42:29 Yeah, I mean, h- first of all, back to your, your business plan, you have to be realistic about...
0:42:34 I mean, people who say, "You know, this'll be $100 million business in three years," you're gonna, you're gonna instantly lose credibility- Hmm... because very few of those animals exist anymore.
0:42:45 And so- Being able to map out through regulatory, clinical, commercial milestones, what are going to be the, the milestones, the events that will really move the needle from a valuation standpoint.
0:42:59 And realistically, what's the capital gonna be required to get there? And then, you know, make sure that you're asking when you're meeting with an investor, what's the size of their fund?
0:43:09 How many, how many portfolio companies are in their fund? What's their normal bite size? What, I mean, what are they willing to invest in total initially?
0:43:19 And then that gives you an idea of am I gonna have to put together a syndicate because of both the amount of capital that's gonna be required for each step or what's gonna be required over the course of the next three to five years.
0:43:33 I mean, I think three to five years is a realistic timeline to be looking at for capital. And then, and then making sure that you, to the... I mean, you can't, I mean, beggars can't be choosers sometimes.
0:43:44 You have to take the investors that are interested. But, you know, understanding your investors, the culture. Talk to, talk to their other portfolio company CEOs.
0:43:53 What's worked, what hasn't worked, what do they like, what don't they like? A- again, it's not a one-size-fits-all situation, but you want your investors to be your partners in the journey, right? Mm-hmm.
0:44:05 And, and do they have, you know, are they on their eighth fund, or is there, this is their first fund? Yeah.
0:44:11 If they're a $100 million fund, that means they're only gonna be a- able to invest smaller amounts, and maybe that's okay depending on where you are, early stage, series A.
0:44:22 But you're starting to see more, you know, for a while, the big, the larger funds were moving away from A and B investing. They want to invest late stage.
0:44:30 Everybody wants, everybody wants a completely de-risk company, right? [laughs] The VCs are acting like PE firms. Yeah.
0:44:37 Um, but more and more you're starting to see because of the impact, the, the downward pressure and valuation in later rounds that's become the norm. Mm-hmm.
0:44:49 You see more and more investors wanting to put together a syndicate up front where they can protect themselves- Mm-hmm... from, from themselves, right?
0:44:58 [laughs] And so as you move out into the later stages, you've got the capital around the table. And I guess the other thing, advice that you give is keep your valuation expectations realistic- Mm, mm...
0:45:11 um, in terms of what it's gonna take. No one ever died from dilution. If you're a founder, it's you die because you don't get capital.
0:45:17 And so an expectation that your company's worth $30 million when you don't have any clinical data, probably not realistic. So just be realistic up front. And, and it's always a trade-off, right? Yeah.
0:45:29 I mean, there's no right or wrong. It's a situation by situation deal, but be realistic. Yeah. There's, there's no doubt.
0:45:35 And, and I think for like newer founders or, you know, that are maybe taking on the CEO role for the first time, understanding that dilution isn't, isn't the, the enemy here, right?
0:45:43 I mean, it's like a necessary- Right... it's, I mean, it's a necessary evil, but like understanding that your investors need to win here too, right? I mean, [laughs] there's- Right...
0:45:49 like with any relationship, there's got to be, there's got to be a win on both, on both sides, and if they're not, they're not winning, that probably isn't, like you're probably not setting yourself up for, for success.
0:45:58 And so, um, yeah, I like your idea of [laughs] dilution is, uh, doesn't mean... No one died from dilution, right? Doesn't mean death, right? [laughs] Right. Yeah. Maybe some expensive water.
0:46:06 If you need some water to survive- [laughs]... may be kind of expensive. You can die. But, but, uh, you know, it's just, it's part of the, part of the game. So I know we got, only got a few minutes left.
0:46:13 I want to get to the rapid fire portion of this interview. Yeah. But again, for everyone listening, sonexhealth.com is the website. We'll link to it in the full writeup on MedSider, but S-O-N-E-X, sonexhealth.com.
0:46:22 Highly encourage you to, um, check out the technology and the company.
0:46:25 Uh, it's really, really cool stuff, really cool space, um, especially with something so, so obviously needed, right, for, for carpal tunnel as we've kind of chatted about throughout the- the, uh, the last hour here.
0:46:35 So, uh, with that said, Bob, rapid fire, uh, portion of the interview here. Feel free to kind of, um, answer rapid fire portion. If you want to expand a little bit, that's totally fine too.
0:46:42 But, um, when you think about, take us out to kind of mid-2027, a year from now, what are you most excited about? Demonstrating adoption and utilization, but adoption. I mean, any...
0:46:51 To get to the growth levels that this needs to get to, we've got to accelerate docs through the, the training pipeline and, and increase the, the number of physicians doing the procedures.
0:47:01 And, and that's gonna come with predictable payment.
0:47:04 We've got the other, the other things that they would worry about when, in terms of clinical data and, and outcomes are there, and so now it's just driving adoption and making sure that the, the payment's consistent.
0:47:14 Yeah, yeah. So much work over the past h- handful of years to get to this point, so it'll be fun to kind of watch, uh, watch your team execute over the next year. Let's say we're in, in, in maybe Minneapolis.
0:47:24 We're, you know, uh, just finished up a, a dinner near m- Lake Minnetonka or something like that, right?
0:47:29 What's the, uh, what's the one lesson that you want every, uh, you think every med tech entrepreneur should really, should really understand? Networking.
0:47:37 Making sure that, that you're, you, you, you're building a support network of, uh... Because as, as a, as a young entrepreneur, you're not going to know.
0:47:46 You're not gonna ha- you won't have the ability to look around the corners because you haven't been to the corners yet. And so surround yourself with people who can be colleagues and mentors- Mm...
0:47:56 um, within, within different areas of expertise and reach out for, reach out for help. There's no such thing as a dumb question.
0:48:03 People wanna help the next generation to be successful and, and use that, build and use that network. Yeah. And you're, you're a good example of that, right?
0:48:12 Willingness to kind of come on the program, uh, two times now, right? Yeah. And share, share a lot, a lot of, uh, lot of super helpful, uh, lessons learned. Um, all right, last question.
0:48:20 Um, anything that you'd, uh, you'd whisper in the ears of the, uh, the younger Bob Paulsen if you could, uh, go back in time? Don't be afraid to make mistakes. Mm. I mean, there, there's no such...
0:48:29 I mean, a mistake, if you keep making the same mistake again and again, that, you're not learning your lesson.
0:48:34 But know that whatever you think is gonna happen in the next six months is gonna change, whatever expectations you have, and just be prepared for that. And, and when something doesn't work, you know, fail fast.
0:48:45 Be prepared to, to pivot and have a plan B- Already kind of thought out, what if, if this doesn't work, what am I gonna do? Mm-hmm.
0:48:53 And surround yourself with build teams of people who are culturally aligned, who have the same vision and values, but that are smarter than you.
0:49:03 There's no such thing as you, you need really talented, experienced people who also have a risk profile that fits- Mm... the business that we've chose to, to get into, which is full of uncertainty.
0:49:17 [laughs] No doubt, no doubt. It's a good way to sum it up, and I, I couldn't agree more with finding not only alignment in terms of, uh, or fi- finding smart people, right?
0:49:26 Uh, but also what those that are willing to kind of take a, take a little bit of risk alongside you. So, um, Bob, I can't thank you enough for coming on the program, uh, twice now.
0:49:34 This has been, been fun to catch up, uh, especially to learn a little bit more about, about Sonix Health too. Well, thanks, Scott. Appreciate the opportunity. Great to see you. Yeah, great to see you again.
0:49:41 I'll have you hold on the line here, but, uh, for everyone listening, you made it this far. Appreciate your attention as always. Again, sonixhealth.com is the website.
0:49:47 We'll link to in the full write-up on MedSider if you want to read a lot of these, uh, these key critical lessons learned that Bob shared throughout the last hour.
0:49:54 Those full write-ups on MedSider allow you to kind of, uh, um, capture or the, the, the, the typically do a, a decent job of capturing a lot of this in, in kind of the written form.
0:50:01 So thanks everyone for your attention as always. Until the next episode of MedSider Goes Live, everyone take care. [upbeat music] Hey, it's Scott again. One quick thing before you go.
0:50:08 You see, I love bringing you insightful conversations with the best founders and CEOs of medical device and health technology startups.
0:50:14 But here's the thing, I'd be super grateful if you could help me reach even more ambitious doers who share our passion.
0:50:19 So if you found value in this podcast, if you found yourself nodding your head while listening, or if you simply enjoy what we're doing with MedSider, please take a moment to leave us a review. It's super easy.
0:50:27 Just open your Apple Podcasts app or the podcasts app of your choice. Search for our show and scroll down to the ratings and review section.
0:50:34 Leave your honest thoughts and hit that five-star rating if you think we're worthy.
0:50:37 Your feedback is incredibly important, and it's the best way to ensure we keep bringing you awesome discussions with leading founders and CEOs. So take a moment to be a good friend and leave that review today.
0:50:46 As always, thanks for being a part of our journey and for helping MedSider continue to grow and evolve. Your support is greatly appreciated. All right, enough talk about reviews.
0:50:53 Stay tuned for another informative episode coming at you soon. [upbeat music]
